Loading...
•
Dec 31, 2024
Biogen Q4 2024 Earnings Report
Key Takeaways
Biogen reported Q4 2024 revenue of $2.46 billion, a 3% increase year-over-year. GAAP diluted EPS was $1.83, up 7% YoY, while Non-GAAP diluted EPS reached $3.44, up 17% YoY. Growth was primarily driven by rare disease revenue and biosimilars, which offset declines in multiple sclerosis products.
Forward Guidance
Biogen expects FY 2025 revenue to decline by a mid-single digit percentage, driven by further declines in multiple sclerosis product revenue, partially offset by growth in product launches.
Positive Outlook
- Continued revenue growth from LEQEMBI and SKYCLARYS.
- FDA approval for LEQEMBI intravenous maintenance dosing.
- Cost reductions through the Fit for Growth program.
- Pipeline expansion with key late-stage assets.
- Stable operating margin expected for 2025.
Challenges Ahead
- Declining multiple sclerosis product revenue.
- Foreign exchange headwinds impacting financials.
- Increased competition in rare disease treatments.
- Uncertainty around Alzheimer’s collaboration revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...